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Abstract
Background: Akt/PKB is a serine/threonine kinase that has attracted much attention because of its
central role in regulating cell proliferation, survival, motility and angiogenesis. Activation of Akt in breast
cancer portends aggressive tumour behaviour, resistance to hormone-, chemo-, and radiotherapy-induced
apoptosis and it is correlated with decreased overall survival. Recent studies have identified novel tumor-
specific substrates of Akt that may provide new diagnostic and prognostic markers and serve as
therapeutic targets. This study was undertaken to identify pAkt-interacting proteins and to assess their
biological roles in breast cancer cells.
Results: We confirmed that one of the pAkt interacting proteins is the Elongation Factor EF1α. EF1α
contains a putative Akt phosphorylation site, but is not phosphorylated by pAkt1 or pAkt2, suggesting that
it may function as a modulator of pAkt activity. Indeed, downregulation of EF1α expression by siRNAs led
to markedly decreased expression of pAkt1 and to less extent of pAkt2 and was associated with reduced
proliferation, survival and invasion of HCC1937 cells. Proliferation and survival was further reduced by
combining EF1α siRNAs with specific pAkt inhibitors whereas EF1α downregulation slightly attenuated the
decreased invasion induced by Akt inhibitors.
Conclusion: We show here that EF1α is a pAkt-interacting protein which regulates pAkt levels. Since
EF1α is often overexpressed in breast cancer, the consequences of EF1α increased levels for proliferation,
survival and invasion will likely depend on the relative concentration of Akt1 and Akt2.
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Breast cancer is the most common cancer among women
in the European Union: each year, 60,000 women die of
breast cancer and 150,000 new cases are diagnosed. Pro-
liferation and survival of breast cancer cells are regulated
by steroid hormones, growth factors and their receptors
through the activation of signal transduction pathways
which, in many cases, are aberrantly activated [1]. The
phosphatidylinositol-3 kinase (PI-3K) pathway has cru-
cial roles in breast cancer [2], and can be altered at multi-
ple levels, including mutations of the PI-3K catalytic
subunit [3] or of its "upstream" or "downstream" regula-
tor/effectors such as PTEN and AKT [4,5]. Akt/PKB is a ser-
ine/threonine kinase that has attracted much attention
because of its central role in regulating several cellular
processes such as proliferation, angiogenesis, motility and
survival [6]. Activation of Akt in breast cancer portends
aggressive tumour behaviour, resistance to hormone-,
chemo-, and radiotherapy-induced apoptosis and it is cor-
related with decreased overall survival [7]. Recent studies
have identified novel tumor-specific substrates of Akt that
may provide new diagnostic and prognostic markers and
serve as therapeutic targets [8]. In light of the central role
of Akt in the regulation of cell survival, specific inhibitors
of this kinase might induce apoptosis when used alone or
in combination with standard cancer chemotherapeutics.
In this regard, suppression of Akt activity by small mole-
cule allosteric inhibitors [9] sensitizes many tumour cell
lines to apoptotis induced by DNA damage, microtubule-
binding agents, targeted therapeutics and ionizing radia-
tion [10] suggesting that Akt inhibitors may enhance the
efficacy of chemotherapy and radiotherapy in breast can-
cer. However, the use of Akt inhibitors in anti-cancer ther-
apies should take into account that neoplastic cells
express variable levels of Akt isoforms that may have dif-
ferent functions, including the distinct ability of pAkt1 or
pAkt2 to regulate migration and invasion of breast cancer
cells [11,12].
This study was undertaken to identify additional pAkt-
interacting proteins and to assess their biological roles in
breast cancer cells. To this end, we used anti-pAkt immu-
noprecipitation followed by mass spectrometry of pAkt-
associated proteins; of several interacting proteins con-
taining putative Akt phosphorylation sites (RXRXX S/T
Ψ), we selected for further studies the eukaryotic Elonga-
tion Factor 1 alpha (EF1α).
EF1α consists of two isoforms, EF1α1 and EF1α2, that
share >90% sequence identity and have the same function
in mRNA translation [13], but markedly different expres-
sion patterns [14,15]. Both proteins appear to be involved
in tumour development and progression [16] and, rela-
tive to normal tissues, expression of EF1α1 and EF1α2 is
more abundant in breast cancer samples [17]. Since
EF1α1 is expressed at high levels in normal breast tissues
while EF1α2 is barely detectable, overexpression of EF1α2
is more likely be biologically relevant in breast cancer.
Recent studies have also correlated the expression of
EF1α2 with ER/HER-2 expression, lymph node status, sur-
vival, tumor size and p53 mutations [17,18].
In this study, we investigated the functional relationship
between EF1α and Akt and the biological consequences of
downregulating EF1α expression for proliferation, sur-
vival and invasion of breast cancer cells. We show here
that EF1α binds only to pAkt but is not an in vitro sub-
strate of active Akt1 or Akt2. Downregulation of EF1α
expression led to decreased expression of pAkt1 and to
less extent of pAkt2, inhibited proliferation, colony for-
mation and invasion and promoted apoptosis of
HCC1937 cells. The combination of EF1α siRNA with
pAkt inhibitors further reduced proliferation, survival and
clonogenic potential of HCC1937 cells, suggesting that
these effects are, in part, Akt-independent; downregula-
tion of EF1α expression attenuated the inhibition of cell
motility induced by Akt inhibitors, consistent with the
possibility that complete inhibition of pro-metastatic
Akt1 activity by EF1α RNAi promotes a slight increase in
the invasiveness of HCC1937 cells. Together, these obser-
vations suggest that EF1α is a regulator of Akt activity and
that the biological consequences of modulating EF1α
expression in breast cancer cells reflect Akt-dependent and
-independent mechanisms.
Results and discussion
Identification of phospho-Akt interacting proteins
To identify novel pAkt- interacting proteins in breast can-
cer cells, proteins associated with pAkt were analyzed by
mass spectrometry. To this end, whole lysates from
HCC1937 or SkBr3 breast cancer cells were immunopre-
cipitated with an anti-pAkt antibody and the pAkt interac-
tome was compared to that from anti-Akt1/Akt2
immunoprecipitates (IPs) of pAkt-depleted lysates (data
not shown). Proteins interacting with pAkt in SkBr3 cells
were also identified by comparing the anti-Akt IPs of
untreated cells and of cells treated with the dual pAkt1/
pAkt2 (pAkt1/2) Merck's inhibitor [9]. The anti-Akt IPs
were then subjected to 2-D electrophoresis and visualized
by silver staining (data not shown). Together, these two
procedures allowed us to identify several proteins prefer-
entially or exclusively present in the pAkt interactomes.
EF1α interacts with phospho-Akt
Spots predominantly present in the anti-pAkt IPs were
excised from the gels and subjected to tryptic digestion for
mass spectrometry identification. One of the p-Akt inter-
acting protein identified in the HCC1937 and SkBr3 cells
is EF1α, previously shown to activate Akt [19].
To confirm the interaction between pAkt and EF1α, anti-
pAkt and anti-Akt1/2 IPs from pAkt-depleted SkBr3 cellPage 2 of 11
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EF1α antibody. EF1α was detected as a 50 kDa band only
in the anti-pAkt IPs (Fig. 1b and 1c). Co-immunoprecipi-
tation/Western blot experiments performed in HCC1937
cells showed identical results (see Additional File 1).
To further characterize the specificity of the pAkt-EF1α
interaction, additional experiments were performed with
antibodies specific for the Akt1 and Akt2 isoforms in
lysate of untreated or pAkt inhibitor-treated cells.
Treatment with the Akt1/2 inhibitor led to complete dis-
appearance of pAkt in the HCC1937 cell lysate (Fig. 2a,
lane 3); instead, levels of pAkt in lysate of cells treated
with the Akt2 inhibitor were still detectable (Fig. 2a, lane
2), suggesting that they represent residual pAkt1 and that
Akt2 is the predominantly phosphorylated isoform in
HCC1937 cells. Levels of EF1α, total Akt1 and total Akt2
remained constant after treatment with the inhibitors
(Fig. 2a, lanes 1–3). EF1α was detectable in the anti-Akt2
IPs from untreated cells and, at lower levels, in the anti-
Akt2 IP from lysate of Akt inhibitor-treated cells (Fig. 2a,
lanes 5 and 6) suggesting that low levels of pAkt2 are still
Interaction between EF1α and Akt in SkBr3 cellsFigure 1
Interaction between EF1α and Akt in SkBr3 cells. 
SkBr3 whole cell lysates and lysates of SkBr3 cells subjected 
to anti-pAkt (Ser473) IP in saturating conditions to deplete 
the active kinase were immunoprecipitated with anti-pAkt or 
anti-Akt1/Akt2 antibody, respectively. IPs were separated in 
two equal amounts and subjected to SDS-PAGE and western 
blotting using anti-Akt1/2 (panel b) and anti-pAkt (panel c) 
antibodies to distinguish pAkt and unphosphorylated Akt and 
to avoid superimposition of adjacent bands and background 
interference. Levels of associated EF1α were also detected in 
both membranes. Western blots show: (a) expression of 
pAkt and EF1α in whole cell and p-Akt-depleted lysates. 
Expression of β-Actin was used as loading control; expres-
sion of total Akt (Akt1/Akt2) and EF1α (b) or of pAkt and 
EF1α (c) in the anti-pAkt and in the anti-Akt (Akt1/Akt2) IPs 
from p-Akt-depleted SkBr3 cell lysate. In the anti-Akt1/2 IPs 
obtained after pAkt depletion, levels of residual pAkt (panel 
c) were negligible.
(a) Western blotting of HCC1937 cell lysates and anti-Akt2 or anti-Akt1 IPs by anti-EF1α, anti-pAkt Ser473, anti-Akt1 and anti-Akt2 antibodiesFigur  2
(a) Western blotting of HCC1937 cell lysates and 
anti-Akt2 or anti-Akt1 IPs by anti-EF1α, anti-pAkt 
Ser473, anti-Akt1 and anti-Akt2 antibodies. Selective 
inhibitors of pAkt2 and pAkt1/2 were used to reduce the 
concentration of active pAkt. (b) Western blot shows 
expression of pAkt, Akt1, Akt2 and EF1α in untreated and 
pAkt1/2 inhibitor-treated SkBr3 cell lysate (lanes 1 and 2) 
and in anti-pAkt (from untreated cell lysates) and anti-Akt1/2 
IPs (from pAkt inhibitor-treated cells) (lanes 3 and 4). (c) 
Western blot shows co-immunoprecipitation of HA-tagged 
pAkt1 and EF1α in SkBr3 cells transfected with HA-tagged 
Myr-Akt1 (lane 2) or T308A/S473A Akt1 (lane 3) expression 
vector. Lysate of SkBr3 wild type cells (lane 1) was used as 
control.Page 3 of 11
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itor-treated cells.
EF1α was also found in the anti-Akt1 IP (Fig. 2a, lane 7),
and formation of the complex appears to depend on Akt1
phosphorylation since the amount of immunoprecipi-
tated EF1α was markedly reduced in cells treated with the
Akt1/2 inhibitor (Fig. 2a, lane 9).
The phosphorylation-dependent association of Akt with
EF1α was also tested in untreated and in pAkt1/2 inhibi-
tor-treated SkBr3 cells. Also in this case, EF1α was found
exclusively in the anti-pAkt IP (Fig. 2b, lane 3).
The association of pAkt-1 and EF1α was further assessed
in SkBr3 cells transfected with HA-tagged Myr-Akt1 or the
phosphorylation-deficient T308A/S473A Akt1 mutant.
Ectopically expressed Myr-Akt1 was abundantly phospho-
rylated (anti-phospho Ser473 western blotting) and inter-
acted with endogenous EF1α (Fig. 2c, lane 2); by contrast,
the double mutant T308A/S473A Akt1 was not phospho-
rylated and failed to interact with EF1α (Fig. 2c, lane 3).
In vitro kinase assays in the presence of EF1α
The interaction of EF1α with pAkt and the finding that
EF1α contains a putative Akt phosphorylation site (amino
acids 67–72) suggested that EF1α might be an Akt sub-
strate. Thus, we synthesized a GST fusion protein (GST-
EF1α) that contains amino acids 1–173 of human EF1α
and includes the putative Akt phosphorylation site and
surrounding amino acids.
GST-EF1α, GST alone as negative control and histone H2B
as positive control, were used as potential "in vitro" sub-
strates of active Akt isoforms 1 and 2. Phosphorylation,
detected by means of phosphocellulose filters (Fig. 3, pan-
els a and b) and SDS/PAGE and autoradiography (see
Additional File 2) showed that the GST-EF1α fusion pro-
tein is not a pAkt1 (panel a) or pAkt2 (panel b) substrate,
whereas histone H2B, used as positive control, was readily
phosphorylated.
To further investigate whether EF1α is a bona fide sub-
strate, a short peptide that includes the putative Akt phos-
phorylation site (EFtide) was used as pAkt1 and/or pAkt2
substrate in "in vitro" kinase assays. In these experiments,
a specific peptide substrate (AKTide) common to pAkt1
and pAkt2 was used as positive control. In three separate
experiments, the EF1α peptide was not phosphorylated
while the AKTide peptide was readily phosphorylated
(Fig. 3, panel c and d).
Silencing of EF1α expression suppresses pAkt levels in 
breast cancer HCC1937 cells
To investigate the function of EF1α in breast cancer cells,
EF1α expression was silenced by RNA interference using
pre-determined conditions (see Additional File 3). 24 h
after transfection with the EFsiRNA, cells were lysed and
extracts analysed by SDS-PAGE and western blotting with
specific antibodies to test the effects of EF1α downregula-
tion on expression and activation of Akt proteins (Fig. 4a).
Since the siRNA used for RNA-interference does not dis-
tinguish between EF1α1 and EF1α2, western blots were
performed with an antibody detecting both isoforms or
with an antibody specific for EF1α; both confirmed that
total EF1α levels and expression of EF1α2 were downreg-
ulated in HCC1937 cells treated for 24 h with the EF1α
siRNA (Fig. 4a). Total levels of Akt1 and Akt2 were not
(a and b): Phosphorylation of GST fusion protein containing ami o acids 1–173 of human EF1α by AktFigure 3
(a and b): Phosphorylation of GST fusion protein con-
taining amino acids 1–173 of human EF1α by Akt. 
Phosphorylation of GST-EF1α by Akt 1 and Akt 2 is reported 
in panel a and b, respectively, in comparison with histone 
H2B and GST used as controls. 1.5 μg of each substrate was 
incubated with 100 ng of Akt isoforms for 45 min in the pres-
ence of 50 μM [γ33P] ATP (specific activity, 4000 cpm/pmol) 
as detailed in Materials and Methods. Data are the mean of 
three independent experiments with SD indicated by vertical 
bars. (c and d): Phosphorylation of EF1α KAERERGITID pep-
tide (EFtide) by Akt. 100 ng of active Akt 1 (panel c) or 2 
(panel d) was incubated for the indicated time with peptide 
KAERERGITID (EFtide) or Akt substrate peptide RPRAATF 
(AKTide). Phosphorylation of EFtide (Star) and AKTide 
(Black dot) was performed at 1 mM and 25 μM concentra-
tion, respectively. The amount of 33P incorporated was 
determined as described in the Materials and Methods. Data 
reported are the mean of three independent experiments.Page 4 of 11
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imately 75% lower), as shown by anti-Ser473 and anti-
Thr308 Western blotting (Fig. 4a).
To assess whether downregulation of EF1α expression was
associated with decreased phosphorylation of a specific
Akt isoform, Akt1 and Akt2 were immunoprecipitated by
use of isoform-specific antibodies and levels of pAkt
assessed by analysis of Ser 473 phosphorylation. As
shown in Fig 4b, downregulation of EF1α expression led
to a marked decrease of pAkt1 whereas levels of pAkt2
were reduced less.
Thr308 is phosphorylated by PDK1 directly [20], while
Ser473 is phosphorylated by TORC2, a complex of four
proteins [21]; thus, we began to investigate the role of
EF1α in Akt activation by assessing whether it forms a
complex with PDK1. Upon transfection in SkBr3 cells,
FLAG-tagged PDK1 was in complex with endogenous
EF1α and pAkt but not with β-actin (Fig. 4c), raising the
possibility that EF1α interacts with PDK1 facilitating
Akt\phosphorylation at Thr308.
Effect of EF1α downregulation on colony formation of 
breast cancer cells
To investigate the role of EF1α for breast cancer cell sur-
vival, colony formation of HCC1937 cells was assessed
after treatment with the EF1α siRNA. 24 h after transfec-
tion, 3,000 cells were plated in 60-mm diameter dishes
and colonies were counted 14 days later. The number of
colonies formed by EF1α siRNA-transfected HCC1937
cells was approximately 30% lower of that from non-
transfected parental cells or cells transfected with CTRL
siRNA (Fig. 5) and the difference was statistically signifi-
cant [Student's t-test, P < 0.05]. A similar inhibitory effect
of the EF1α siRNA (approximately 27%) was also
observed in soft agar colony formation assays (see Addi-
tional File 4). To determine whether further suppression
of pAkt activity could enhance the inhibitory effect of the
EF1α siRNA on colony formation, HCC1937 cells were
transfected with EF1α siRNA or CTRL siRNA and 24 h
later seeded in 60-mm diameter dishes (3,000 cells/dish)
in the presence of pAkt inhibitors and assessed in clono-
genic assays (Fig. 5). Cells transfected with EF1α siRNA
and treated with the Akt1/2 inhibitor formed 38% fewer
colonies than cells treated with CTRL siRNA only, 8%
fewer colonies than cells treated with the EF1α siRNA and
18% fewer colonies than cells treated with CTRL siRNA
and the Akt inhibitors. Downregulation of EF1α expres-
sion and pAkt activity also led to reduced colony forma-
tion of SkBr3 cells (see Additional File 5).
Effect of EF1α downregulation on cell cycle activity of 
HCC1937 cells
To assess whether inhibition of EF1α expression affects
the proliferation of HCC1937 cells, we compared the cell
cycle activity of CTRL- and EF1α siRNA-transfected
HCC1937 cells by DNA content analysis. As shown in
Table 1, inhibition of EF1α expression by EF1α RNAi
induced a modest increase in the proportion of G1 cells
and a correspondent decrease in S phase cells, in compar-
ison to HCC1937 cells transfected with the CTRL siRNA.
Compared to CTRL siRNA-transfected cells, a higher frac-
tion of cells transfected with the EF1α siRNA had a subG1
DNA content (1.8% vs 5%) which is indicative of apopto-
sis.
Effect of EF1α expression on pAkt, Akt1 and Akt2 levelsFigure 4
Effect of EF1α expression on pAkt, Akt1 and Akt2 levels. a) Western blot shows levels of the indicated proteins 
(including β-actin for normalization) in HCC1937 cells 24 h after transfection with CTRLsiRNA or EF1α siRNAs; b) Western 
blot shows expression of pAkt in anti-Akt1 or anti-Akt2 IPs of CTRL or EF1α siRNA-transfected HCC1937 cells; c) Western 
blot shows pAkt and EF1α expression in lysate or IPs (anti-FLAG or anti-EF1α) of SkBr3 cells transfected with FLAG-PDK1.Page 5 of 11
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was also analysed after EF1α RNAi and pAkt inhibition.
Treatment with the Akt inhibitor of EF1α siRNA-trans-
fected cells suppressed the cell cycle more efficiently with
a statistically significant increase in the fraction of G1
phase cells (77% in EF1α siRNA-silenced and Akt inhibi-
tor-treated cells vs. 63.3% for cells transfected with the
CTRL siRNA and treated with Akt1-1/2 and 69.4% for
cells transfected with the EF1α siRNA) and a proportional
statistically significant decrease in the number of G2
phase cells (7.6% vs. 15.8% or 17.2%, respectively). The
number of apoptotic cells was not affected by the simulta-
neous EF1α downregulation and treatment with the pAkt
inhibitor.
Effect of EF1α downregulation on invasion of HCC1937 
cells
EF1α binds to actin filaments and microtubules and is
involved in actin cytoskeleton remodelling [22,23]. Fur-
thermore, ectopic EF1α2 expression significantly
enhanced migration of BT549 breast cancer cells [19]. To
assess whether endogenous levels of EF1α were required
for breast cancer cell invasion, HCC1937 cells were trans-
fected with the EF1α siRNA to knock-down EF1α expres-
sion and invasion tested using Matrigel-coated transwell
chambers. Compared to HCC1937 cells transfected with
the CTRL siRNA, those transfected with the EF1α siRNA
showed approximately a 50% decrease in migration [Stu-
dent's t-test, P < 0.05]; by contrast, invasion of CTRL
siRNA-transfected HCC1937 cells was only slightly
reduced compared to parental HCC1937 cells, probably
reflecting transfection toxicity in this assay (Fig. 6).
Lower pAkt activity in EF1α siRNA-transfected HCC1937
cells might be involved in the reduced invasion of these
cells; thus, the number of siRNA-transfected HCC1937
cells migrated trough Matrigel was assessed after treat-
ment with the pAkt2 or the dual pAkt1/pAkt2 inhibitor.
As shown in Fig. 6, simultaneous inhibition of Akt1 and
Akt2 activity caused approximately an 80–85% decrease
in invasion; interestingly, the pAkt2 inhibitor was slightly
more potent than the dual pAkt1/pAkt2 inhibitor in sup-
pressing the invasiveness of HCC1937 breast cancer cells.
Since expression of activated Akt1 blocked the in vitro
migration and invasion of three breast cancer cell lines
through Matrigel [24], the more potent effect of the spe-
cific Akt2 inhibitor in our assays could reflect the anti-
migratory activity of residual pAkt1.
Discussion
The goal of the present study was to identify novel pAkt-
interacting proteins and to assess their role in breast can-
cer cells. To this end, pAkt-interacting proteins were iden-
tified by anti-pAkt immunoprecipitation and 2-D
electrophoresis followed by in-gel digestion and mass
spectrometry analysis of spots exclusively or predomi-
nantly present in the pAkt interactome; we reasoned that
a protein interacting with pAkt could be a substrate or a
modulator of Akt activity. One of the pAkt interacting pro-
teins identified in the proteomic analyses was EF1α.
While we were investigating the interaction of EF1α with
Colony formation of HCC1937 cells transfected with EF1α siRNA and/or treated with pAkt inhibitorsFigure 5
Colony formation of HCC1937 cells transfected with 
EF1α siRNA and/or treated with pAkt inhibitors. 
HCC1937 cells were transfected with 100 nM of EF1α or 
CTRLsiRNA and 24 h later counted and plated in 60-mm 
diameter dishes (3,000 cells for dish). For the co-treatment 
with siRNAs and the Akt inhibitor, transfected cells were 
plated in the presence of the Akt inhibitor (final concentra-
tion of 7 μM). After 14 days, cells were fixed and stained with 
crystal violet. Results are representative of three independ-
ent experiments with triplicate counts.
Table 1: Effect of EF1α downregulation and pAkt inhibition on 
cell cycle distribution of HCC1937 cells
Cells G0/G1 S G2/M Apoptosis
CTRLsiRNA 60 18.8 20.3 1,8
EFsiRNA 69.4 10.5 17.2 5
CTRLsiRNA + inhib. 63.3 18.8 15.8 4.6
EFsiRNA + inhib. 77.5 10.5 7.6 6.4
Representative of three different experiments with similar results. 
Values indicate % of cells in different cell cycle phases and apoptosis.Page 6 of 11
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tates with HA-tagged Akt2, possibly through a complex
with β-tubulin. In our mass spectrometry analysis, the
presence of EF1α in the pAkt interactome was confirmed
in several experiments, but β-tubulin was not detected,
suggesting that EF1α and pAkt can also interact independ-
ently of β-tubulin.
Since our anti-pAkt antibody does not distinguish
between the pAkt isoforms, we used antibodies specific
for the Akt 1 or the Akt2 isoform and specific Akt kinase
inhibitors to assess the presence of EF1α in the Akt1 and
Akt2 interactome of HCC1937 cells.
These analyses revealed that the interaction between Akt2
and EF1α depends on the phosphorylation status of Akt2,
the most abundant and active isoform in HCC1937 cells
and in breast cancer tumors [26]. A similar phosphoryla-
tion-dependent mechanism is also involved in the Akt1-
EF1α interaction, since endogenous EF1α was in complex
with Myr-Akt1 but not with the phosphorylation-deficient
double mutant T308A/S473A Akt1.
Many experiments have demonstrated that Akt-depend-
ent signaling pathways are crucial for normal cell growth
and that their deregulation influences cellular responses
associated with the cancer phenotype [2,27]
Since abnormal Akt activation is well documented in
many human malignancies [7] and EF1α might have
oncogenic effects in breast cancer [17,28], the interaction
between EF1α and pAkt2 (and/or pAkt1) could represent
an important mechanism for the regulation of Akt-
dependent signaling pathways in cancer.
Although EF1α associates with pAkt1 and pAkt2 and con-
tains a putative Akt phosphorylation site, our "in vitro"
kinase assays indicate that is not an Akt substrate. How-
ever, down-regulation of EF1α expression by RNAi led to
decreased pAkt expression with an apparently more pro-
nounced effect on the Akt1 isoform, consistent with the
reported Akt activation by ectopic EF1α2 expression [19].
The mechanisms involved in the regulation of Akt activity
by EF1α are unknown; our finding that EF1α interacts
with PDK1 raises the intriguing possibility that it forms a
complex with PDK1 and Akt facilitating PDK1 phosphor-
ylation of Akt at Thr 308.
Downregulation of EF1α expression diminished the clo-
nogenic potential of HCC1937 and SkBr3 cells, suggesting
that EF1α regulates this aspect of breast cancer cell pheno-
type; suppression of Akt activity by Akt inhibitors induced
only a modest but not statistically significant decrease of
colony formation and combining the EF1α siRNA with
Akt inhibitors had only a modest additive effect.
DNA content analysis revealed that EF1α downregulation
and pAkt1/pAkt2 inhibition suppressed cell proliferation
and induced apoptosis.
Since the role of pAkt-substrates in cell cycle progression
and apoptosis is well established [2,29,30], the effect of
EF1α downregulation on the cycle distribution of
HCC1937 cells could be due to decreased Akt activity.
However, the effect of EF1α siRNA was more potent than
that pharmacological inhibition of pAkt1/pAkt2 and was
amplified by simultaneous treatment with the pAkt1/
pAkt2 inhibitors.
Together, these data suggest that the effects of EF1α down-
regulation on proliferation and survival of breast cancer
cells are, in part, Akt-independent probably reflecting the
role of EF1α in mRNA translation and protein synthesis.
EF1α depletion by RNA-interference also decreased the
invasion of HCC1937 cells, suggesting that EF1α might
have a role in tumor metastasis. Previous studies have
shown a functional relationship between EF1α expression
and invasion; in particular, expression of EF1α2 appears
to increase cell migration, EF1α mRNA levels correlate
with increased metastatic potential in mammary adeno-
carcinoma and EF1α protein is overexpressed in meta-
static compared to non metastatic cells [16,19,31]
However, Kulkarni et al. [18] reported that EF1α2 expres-
sion is associated with good prognosis and suggested that
Invasion of HC1937 cells measured by matrigel assaysFigure 6
Invasion of HC1937 cells measured by matrigel 
assays. Numbers of migrated cells were counted and each 
data point represents the mean of three independent experi-
ments.Page 7 of 11
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program. The modest effect of EF1α downregulation on
the metastatic potential of HCC1937 cells is likely to
reflect the partial inhibition of pro-metastatic pAkt2 more
than loss of anti-metastatic pAkt1 as pAkt2 is the predom-
inant Akt isoform in HCC1937 cells. Consistent with this
interpretation, direct inhibition of Akt activity by the Akt
inhibitors used here suppressed the invasiveness of
HCC1937 cells more efficiently than EF1α downregula-
tion and the specific Akt2 inhibitor was slightly more
potent of the dual Akt1/Akt2 inhibitor, a finding in keep-
ing with Akt1 and Akt2 having distinct roles in regulating
the motility of breast cancer cells [11,31,32]. The simulta-
neous EF1α depletion and pAkt inhibition did not reduce
further the invasiveness of HCC1937 cells; if anything, the
effect of the Akt inhibitors was attenuated by EF1α down-
regulation, consistent with a more profound inhibition of
anti-metastatic pAkt1. However, the effect of active Akt1
on migration and invasion might be cell line and/or cell-
type specific [32,33], raising the possibility that downreg-
ulation of EF1α might have different effects on the migra-
tion of other cancer lines, depending on the relative
concentration and activity of Akt isoforms. Since the dif-
ferences in migration induced by the combination of
EF1α siRNA and the Akt inhibitors were modest (only that
between CTR siRNA plus Akt2 inhibitor versus EF1α
siRNA plus Akt2 inhibitor was statistically significant), it
is also possible that they reflect experimental variability.
Conclusion
In summary, we have shown that EF1α is a pAkt-interact-
ing protein which modulates the activity of pAkt1 and
pAkt2 and regulates the proliferation, survival and motil-
ity of breast cancer cells. Our results are consistent with
previous studies suggesting that EF1α promotes tumori-
genesis and indicate that expression of EF1α is required
for many properties of breast cancer cells via Akt-depend-
ent and -independent mechanisms. The Akt-dependent
effects of EF1α may be, in part, due to the concentration
of Akt isoforms, suggesting that investigating the mecha-
nisms responsible for differential Akt isoform expression
may be necessary to further understand the role of EF1α
in the biology of breast cancer cells.
Methods
Plasmids
HA-tagged Myr-Akt1 and T308A/S473A-Akt1 in the
pCMV6 vector were the kind gift of Dr. A. Bellacosa (IRE,
Roma, Italy); FLAG-tagged PDK1 was the kind gift of Dr
H. Ha (Chungbuk National University, KOREA)
Cell lines and cell cultures
HCC1937 cells were grown in RPMI 1640 medium (Invit-
rogen-GIBCO, Carlsbad, CA, USA) supplemented with
10% fetal bovine serum (FBS, Gibco), 2 mM glutamine,
100 U/ml penicillin and 100 ug/ml streptomycin.
SKBr3 cells were cultured in Dulbecco's modified Eagle's
medium (Gibco) supplemented with 10% FBS (Gibco), 2
mM glutamine, 100 U/ml penicillin and 100 μg/ml strep-
tomycin. Akt inhibitors (pAkt1/2 and pAkt2) (Barnett et
al, 2005) were kindly provided by Dr. DeFeo-Jones
(Merck Research Laboratories, West Point, PA, USA). The
pAkt1/2 and the selective pAkt2 inhibitors were used at a
final concentration of 7 μM for 24 h, conditions at which
pAkt was essentially undetectable in HCC1937 cells (see
Additional File 6). Cells were treated when 60% conflu-
ent.
Immunoprecipitation
For immunoprecipitation of endogenous or ectopic HA-
tagged Akt, lysates were precleared with protein G Agarose
beads (Oncogene/Calbiochem Laboratories, Cambridge,
MA) at 4°C for 45 min and incubated with specific anti-
bodies using conditions suggested by the vendor. To
achieve pAkt depletion, saturating anti-pAkt immunopre-
cipitation was performed for 5 h with an excess of anti-
pAkt antibody-conjugated beads. After beads removal,
lysates were incubated with the indicated antibody pre-
coated with protein G Agarose beads for 2 h at 4°C. Beads
were washed once with lysis buffer and twice with 10 mM
Tris-HCL pH 7.4. For IPs, monodimensional electro-
phoresis and western blot analysis, beads were eluted with
2× Laemmli sample buffer supplemented with 100 μM
DTT at 95°C for 7 min.; for 2D-MS analysis, elution was
carried out using 2D rehydration buffer (8 M Urea, 2%
CHAPS, 50 mM DTT, 30 min/37°C) and appropriate
ampholytes (Bio-Rad).
Protein extraction and western blot
To obtain whole cell lysates, cells were suspended in
detergent lysis buffer, disrupted for 20 min at 4°C on a
rotary shaker and centrifuged at 13.000 × g for 30 min.
The pellet was discarded and protein concentration in the
supernatant measured using a Bredford Protein Assay kit
(Bio-Rad, Richmond, CA, USA). For western blot analysis,
equivalent amounts of proteins and IPs were resolved by
SDS-PAGE, transferred to nitrocellulose membranes and
blotted. The anti-Ser473-pAkt antibody (#4051, 1:1000
dilution) was from Cell Signaling Technology (Denvers,
MA, USA), the anti-EF1α (#sc-12991, 1:800 dilution)
antibody was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA), as were the anti-Akt1 and Akt-2 antibod-
ies (#sc-5298 and #sc-5270, 1:1000 dilution). The anti
EF1α2 antibody was kindly provided by Dr. Abbott (Uni-
versity of Edinburgh, Molecular Medicine Centre, Western
General Hospital, Edinburgh). Anti-HA antibody (#MMS-
101P, 1:000) was from Covance (Berkeley, CA, USA).
Secondary antibodies were peroxidase-labeled and perox-
idase was detected with Enhanced Chemioluminescence
Kit (ECL, Amersham Pharmacia Biotech, UK) or Immo-Page 8 of 11
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USA).
2-Dimensional electrophoresis
Readystrip IPG strip (pH 4–7, 7 cm Bio-Rad) were rey-
drated in 2D rehydration buffer containing the protein
sample. After IEF (Protean IEF cell, Bio-Rad) strips were
subjected to reduction and alchylation reactions (15 min
in rehydration buffer containing 10 mg/ml of DTT fol-
lowed by 15 min in rehydration buffer containing 25 mg/
ml of iodoacetamide). For second dimension's separa-
tion, 7 cm strips were dipped in the SDS running buffer
and placed side by side on the top of the same 10% labo-
ratory-made polyacrylamide gel (size 16 cm × 16 cm) to
equalize the conditions of electrophoresis and stain. Gels
were stained by the Silver Stain method.
In-gel protein digestion and mass spectrometry
After gel staining, bands or spots of interest were excided
from gels with end-removed pipette tip and transferred
into a microcentrifuge tube (0.5 mL). Briefly, protein
pieces were destained by incubation with 200 μl of 1:1
solution 30 mM potassium hexacyano-ferrate (III) and
100 mM sodium thiosulphate, washed twice with 100 μl
of water for 15 min and shrunk with 100% acetonitrile
until the gels turned white. Proteins were then reduced
adding 50 μl of a DTT solution (10 mM DTT in 50 mM
ammonium bicarbonate) and sequentially alkylated
using a IAA solution (55 mM IAA in 50 mM ammonium
bicarbonate). A volume of 30 μl of trypsin (Promega,
Madison, WI) solution (12.5 ng/μl in 25 mM ammonium
bicarbonate) was then added, and the gel pieces were
incubated at 4°C for 30 min. After digestion, trypsin solu-
tion was removed and the samples were incubated at 37°
o/n in the same solution without trypsin. Resulting super-
natant representing peptide solution were recoverd and
concentrated in a vacuum drier (Savant Speed-Vac con-
centrator).
After resuspensin in 5% formic acid, extracted peptides
were sent to C.I.G.S. (Centro Interdipartimentale Grandi
Strumenti, Università di Modena, Italy) and identificated
by ESI/Q-Tof Mass Spectrometry (Waters-Micromass,
Manchester, UK). Peptide identity was determined by
searching the Swiss-Prot database.
Glutathione S-Transferase (GST) Fusion Proteins
To synthesize GST fusion proteins, cDNA segments
encoding parts of EF1α protein (amino acids 1 – 137)
were amplified by RT-PCR from HCC1937 cells and sub-
cloned into the EcoRI-XhoI-digested pGEX5.1 plasmid.
Proteins were expressed in BL21 cells by IPTG induction
(1 mM, 3 h), and purified on glutathione-agarose beads
(Sigma). GST-proteins were eluted in 50 mM Tris-HCl pH
9.0, 30 mM GSH.
Peptide synthesis
Synthetic peptide KAERERGITID (EFtide) corresponding
to amino acids 64–74 of EF1α and RPRAATF (AKTide) a
specific substrate of Akt were synthesized by solid phase
peptide synthesis method using an automatized peptide
synthesizer (model 431-A, Applied Biosystems, Foster
City, CA). Crude peptides were purified by preparative
reverse phase HPLC and purity was evaluated by analyti-
cal reverse phase HPLC (about 95%). Molecular masses of
the peptides were confirmed by mass spectroscopy with
direct infusion on a Micromass ZMD-4000 Mass Spec-
trometer (Waters- Micromass).
In vitro kinase assay
Phosphorylation reactions were performed by incubating
the phosphorylatable protein or peptide substrate in 30 μl
of a medium containing 20 mM HEPES (pH 7,5), 10 mM
MgCl2, 10 mM MnCl2, 1 mM DTT, 50 μM [γ-33P]ATP
(specific activity, 2000 cpm/pmol) and 100 ng of full-
length recombinant active Akt1 (specific activity 124
nmol/min/mg) or Akt2 (specific activity 43 nmol/min/
mg), expressed in Sf9 cells (from SignalChem, Richmond,
BC, Canada) (active Akt1 # A16-10G-05, active Akt2 #
A17-10H-05) for the indicated time at 30°C.
The phosphate incorporated into substrates was evaluated
either by subjecting samples to SDS/PAGE, staining and
autoradiography or using phosphocellulose filters [34].
Values obtained represent the mean of at least three inde-
pendent experiments.
RNA Interference
siRNA duplex oligoribonucleotides corresponding to the
EF1α gene were designed by Block-iT RNAi Designer (Inv-
itrogen). Best results of EF1α downregulation were
obtained by using the following EF1α gene-specific
sequences beginning at nt 607 (named "EFsiRNA"): sense
5' Flo-GCGCCUACAUCAAGAAGAUdTdT 3', antisense 5'
Flo-AUCUUCUUGAUGUAGGCGCTT 3'.
Transfection of siRNA oligos was carried out with Lipo-
fectamine™ 2000 (Invitrogen). Cells were incubated for
24, 48, 72 and 96 h post-transfection and EF1α expression
was detected by western blotting. Fluorescent oligos were
used to determine uptake efficiency and set optimal lipo-
fection conditions.
Colony formation and soft agar assay
24 h after transfection, HCC1937 cells were trypsinized,
counted, suspended in 15% conditioned medium and
seeded for colony formation assays in 60-mm dishes at
3,000 cells per dish. To test the effect of Akt inhibitors,
cells were seeded in medium supplemented with pAkt
inhibitors (7 μM in DMSO) in the dark; equal volume of
DMSO was used in control experiments. After incubation
for 14 days, colonies (>30 cells) were stained with crystalPage 9 of 11
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formed in triplicate.
For soft-agar assays, 5,000 cells were pleated in 60-mm-
diameter tissue culture plates containing 0.35% top low-
melt agarose-0.5% bottom low-melt agarose. After 2
weeks of incubation at 37°C in 5% CO2 and 95% humid-
ified air, colonies that contained 30 or more cells were
counted. Experiments were performed in triplicate.
Invasion Assay
Cell migration was analyzed with the BioCoat Matrigel
Invasion Chambers (BD, Becton-Dickinson, San Jose, CA,
USA). Control, siRNA-transfected and Akt inhibitor-
treated HCC1937 cells were seeded at 40,000 cells in each
upper chamber in RPMI 1640 supplemented with 5%
FBS. Lower chambers were filled with 750 μl of 5% condi-
tioned medium of confluent HCC1937 cells containing
10% of FBS as a chemoattractant. Chambers were incu-
bated for 22 h at 37°C in a humidified 5% CO2 atmos-
phere, then cells in the upper chamber were removed.
Cells adherent to the lower surface of the membrane were
fixed with methanol and stained with crystal violet. Cells
migrated to the lower surface of the filter were considered
to have invaded through the overlying matrix and were
counted.
Flow Cytometry
Adherent cells were trypsinized, centrifuged at 1000 g for
5 min, fixed in ice-cold 70% ethanol and incubated at -
20°C for 2 h. Cells were centrifuged, resuspended in PBS
and incubated with RNAse A (200 μg/ml) for 30 min at
room temperature; then, cells were incubated with pro-
pidium iodide (50 μg/ml) for 30 min at room tempera-
ture in the dark. Quantification of sub-2N DNA was
determined by flow cytometry using Coulter Epics XL
(Beckman Coulter, Fullerton, CA).
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